Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma.
Haematologica. 2017.
PMID: 28971900
Free PMC article.
Clinical Trial.
Search Page
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 1956 | 1 |
| 1966 | 1 |
| 1968 | 1 |
| 1972 | 1 |
| 1975 | 4 |
| 1976 | 4 |
| 1977 | 2 |
| 1978 | 2 |
| 1979 | 2 |
| 1980 | 6 |
| 1981 | 7 |
| 1982 | 10 |
| 1983 | 12 |
| 1984 | 17 |
| 1985 | 17 |
| 1986 | 16 |
| 1987 | 19 |
| 1988 | 17 |
| 1989 | 30 |
| 1990 | 46 |
| 1991 | 45 |
| 1992 | 48 |
| 1993 | 59 |
| 1994 | 61 |
| 1995 | 55 |
| 1996 | 58 |
| 1997 | 64 |
| 1998 | 54 |
| 1999 | 75 |
| 2000 | 102 |
| 2001 | 115 |
| 2002 | 144 |
| 2003 | 143 |
| 2004 | 160 |
| 2005 | 150 |
| 2006 | 174 |
| 2007 | 174 |
| 2008 | 164 |
| 2009 | 209 |
| 2010 | 217 |
| 2011 | 221 |
| 2012 | 235 |
| 2013 | 264 |
| 2014 | 305 |
| 2015 | 344 |
| 2016 | 358 |
| 2017 | 389 |
| 2018 | 398 |
| 2019 | 489 |
| 2020 | 586 |
| 2021 | 679 |
| 2022 | 719 |
| 2023 | 712 |
| 2024 | 242 |
Search Results
7,404 results
Results by year
Citations
1
article
found by citation matching
Search results
Page 1
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study.
Lancet. 2021 Sep 25;398(10306):1157-1169. doi: 10.1016/S0140-6736(21)00889-8. Epub 2021 Sep 8.
Lancet. 2021.
PMID: 34508654
Clinical Trial.
BACKGROUND: Patients with relapsed or refractory B-cell non-Hodgkin lymphoma have few treatment options. ...INTERPRETATION: Single-agent subcutaneous epcoritamab for treatment of patients with relapsed or refractory B …
BACKGROUND: Patients with relapsed or refractory B-cell non-Hodgkin lymphoma have few treatment op …
Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment.
Curr Treat Options Oncol. 2022 Feb;23(2):155-170. doi: 10.1007/s11864-021-00925-1. Epub 2022 Feb 19.
Curr Treat Options Oncol. 2022.
PMID: 35182296
Review.
While there have been numerous advances in the field of non-Hodgkin lymphoma (NHL) over the last decade, relapsed and/or refractory (R/R) NHL remains a challenge and an area with unmet needs. ...
While there have been numerous advances in the field of non-Hodgkin lymphoma (NHL) over the last decade, relapsed …
Epcoritamab: First Approval.
Drugs. 2023 Sep;83(14):1331-1340. doi: 10.1007/s40265-023-01930-4.
Drugs. 2023.
PMID: 37597091
Review.
Epcoritamab (epcoritamab-bysp; Epkinly; Tepkinly()) is a subcutaneously administered CD3CD20 T-cell-engaging bispecific antibody being co-developed by Genmab and AbbVie for the treatment of mature B-cell non-Hodgkin lymphoma subtypes (B-NHLs), including diffu …
Epcoritamab (epcoritamab-bysp; Epkinly; Tepkinly()) is a subcutaneously administered CD3CD20 T-cell-engaging bispecific antibody being co-de …
Glofitamab: First Approval.
Drugs. 2023 Jul;83(10):935-941. doi: 10.1007/s40265-023-01894-5.
Drugs. 2023.
PMID: 37285013
Free PMC article.
Review.
Glofitamab (Columvi()) is a CD20 CD3 T-cell-engaging bispecific monoclonal antibody being developed by Roche for the treatment of B-cell non-Hodgkin lymphomas, including diffuse large B-cell lymphoma (DLBCL). ...Clinical development of glofitamab, as a monoth …
Glofitamab (Columvi()) is a CD20 CD3 T-cell-engaging bispecific monoclonal antibody being developed by Roche for the treatment of B-cell …
Primary CNS Lymphoma.
J Clin Oncol. 2017 Jul 20;35(21):2410-2418. doi: 10.1200/JCO.2017.72.7602. Epub 2017 Jun 22.
J Clin Oncol. 2017.
PMID: 28640701
Free PMC article.
Review.
Primary CNS lymphoma (PCNSL) is a rare form of extranodal non-Hodgkin lymphoma that is typically confined to the brain, eyes, and cerebrospinal fluid without evidence of systemic spread. The prognosis of patients with PCNSL has improved during t …
Primary CNS lymphoma (PCNSL) is a rare form of extranodal non-Hodgkin lymphoma that is typically confined to the …
Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the CART Era.
Front Immunol. 2022 Jul 19;13:909008. doi: 10.3389/fimmu.2022.909008. eCollection 2022.
Front Immunol. 2022.
PMID: 35928819
Free PMC article.
Review.
Diffuse large B-cell lymphoma is an aggressive and biologically heterogeneous disease. R-CHOP is the standard first line therapy and cures more than 60% of patients. Salvage high-dose chemotherapy with autologous stem cell transplant remains the standard second-line …
Diffuse large B-cell lymphoma is an aggressive and biologically heterogeneous disease. R-CHOP is the standard first line therapy and …
Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.
Lancet Oncol. 2016 Aug;17(8):1081-1093. doi: 10.1016/S1470-2045(16)30097-3. Epub 2016 Jun 23.
Lancet Oncol. 2016.
PMID: 27345636
Clinical Trial.
BACKGROUND: Patients with indolent non-Hodgkin lymphoma who fail to achieve adequate disease control with rituximab-based treatment have few treatment options and a poor prognosis. ...INTERPRETATION: Obinutuzumab plus bendamustine followed by obinutuzu …
BACKGROUND: Patients with indolent non-Hodgkin lymphoma who fail to achieve adequate disease control with rituxi …
Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS).
Lancet Haematol. 2019 May;6(5):e254-e265. doi: 10.1016/S2352-3026(19)30026-2. Epub 2019 Mar 29.
Lancet Haematol. 2019.
PMID: 30935953
Clinical Trial.
INTERPRETATION: R-pina and R-pola are potential treatment options in patients with relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma. Pola was selected by the study funder for further development in non-Hodgk …
INTERPRETATION: R-pina and R-pola are potential treatment options in patients with relapsed or refractory diffuse large …
Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study.
J Clin Oncol. 2018 Aug 1;36(22):2259-2266. doi: 10.1200/JCO.2017.76.3656. Epub 2018 Mar 27.
J Clin Oncol. 2018.
PMID: 29584548
Clinical Trial.
Purpose To perform an updated analysis of the randomized phase III GADOLIN trial in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated with obinutuzumab (GA101; G) and bendamustine (B). Patients and Methods Patien …
Purpose To perform an updated analysis of the randomized phase III GADOLIN trial in patients with rituximab-refractory indolen …
Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma.
Blood Adv. 2022 Feb 8;6(3):1025-1037. doi: 10.1182/bloodadvances.2021005954.
Blood Adv. 2022.
PMID: 34941996
Free PMC article.
Glofitamab, a novel CD20xCD3, T-cell-engaging bispecific antibody, exhibited single-agent activity in Study NP30179, a first-in-human, phase 1 trial in relapsed/refractory B-cell non-Hodgkin lymphoma. Preclinical studies showed that glofitamab l …
Glofitamab, a novel CD20xCD3, T-cell-engaging bispecific antibody, exhibited single-agent activity in Study NP30179, a first-in-human, phase …
Cite